CONTACT INFORMATIONBIOGRAPHYCREDENTIALSCLINICAL TRIALSPUBLICATIONSFrank C. Passero, M.D.Contact InformationPhone NumbersAppointment: (585) 276-3000A member of the University of Rochester Medical Faculty GroupgroupAn Accountable Health PartnerassignmentAccepting New PatientsLocationsWilmot Cancer Institute Oncology601 Elmwood AveRochester, NY 14642-0001Oncology: (585) 275-5823Faculty AppointmentsAssistant Professor - Department of Medicine , Hematology/Oncology (SMD) Patient Care SettingCancerBiographyAs a physician I aim to provide patients with an understanding of their medical condition and guidance as they navigate complex medical decisions. I consider honesty, compassion and my medical knowledge as foundational principles upon which I seek to build a trusting patient-physician relationship. Getting to know my patients, their unique circumstances and goals is a key aspect of my practice, in order to provide patients with a personalized plan of care. I obtained my medical degree from Jefferson Medical College in Philadelphia, Pennsylvania and went on to complete internship, residency, and a chief medical residency in Internal Medicine at Scripps Mercy Hospital in San Diego. I pursued my Hematology and Oncology fellowship training at Tufts Medical Center in Boston, Massachusetts where I carried out laboratory research studying the effects of proteasome and HDAC inhibitors in lymphoma. I have a special interest in plasma cell disorders including myeloma and amyloidosis, and would like to provide patients with the opportunity to participate in well-designed clinical trials for these and other related diseases.CredentialsSpecialtiesHematology - American Board of Internal MedicineInternal Medicine - American Board of Internal MedicineMedical Oncology - American Board of Internal MedicineEducation2010MD | Thomas Jefferson UniversityPost-doctoral Training & Residency07/01/2014 - 06/30/2017Fellowship in Hematology/Oncology at Tufts Medical Center07/01/2011 - 06/30/2014Residency in Internal Medicine at Mercy Hospital and Medical Center6/24//2010 - 06/23/2011Internship in Internal Medicine at Mercy Hospital and Medical CenterVIEW ALL expand_moreClinical TrialsA Phase II Study of Steroid Sparing Treatment With Daratumumab and Lenalidomide in Newly Diagnosed Transplant Ineligible Patients With Multiple MyelomaLead Researcher: Frank C Passero The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma. View Study Details A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIb AL AmyloidosisLead Researcher: Frank C Passero AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine if CAEL-101 improves the overall survival in Patients with cardiac AL Amyloidosis. View Study Details A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIa AL AmyloidosisLead Researcher: Frank C Passero AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine if CAEL-101 improves the overall survival in Patients with cardiac AL Amyloidosis. View Study Details PublicationsJournal Articles11/26/2019Evens AM, Konry T, David K, Mokhtar M, Chen Y, Beheshti A, Passero F, Purvey S, Sarkar S, Ravi D. "Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma." Leukemia.. 2019 Nov 26; Epub 2019 Nov 26. 8/26/2019Evens AM, David KA, Beheshti A, McDonald JT, Ravi D, Passero FC. "Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma." British journal of haematology.. 2019 Aug 26; Epub 2019 Aug 26. 7/29/2019Lipe B, Passero FC, Gleber C, Portuguese AJ. "A review of thrombotic microangiopathies in multiple myeloma." Leukemia research.. 2019 Jul 29; 85:106195. Epub 2019 Jul 29. VIEW ALL PUBLICATIONSClose WindowSchedule an appointment with Frank C. Passero, M.D.Please answer the following questions to help us find the right appointment for you.Important: If you believe that you have a medical or psychiatric emergency, please call 911 or go to the nearest hospital. This website is not intended for emergency care.Have you seen this provider in the last 2 years?YesNoExisting Patient Schedule or request a follow up appointment online through MyChart. If you do not have a MyChart account, please close this window and call the appointment phone number. Frank C. Passero, M.D. is currently scheduling for the following appointment type(s): Our policy does not permit patients to establish care with multiple providers within the same practice or specialty without prior approval. If you choose a new provider in the same office, we will cancel the appointment. Please contact the office directly with questions on this policy.